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Edited by Felix WielandAbstract The homopentameric B-subunit of Shiga toxin
(STxB) is used as a tool to deliver antigenic peptides and pro-
teins to the cytosolic compartment of dendritic cells (DCs). In
this study, a series of interface mutants of STxB has been con-
structed. All mutants retained their overall conformation, while
a loss in thermal stability was observed. This eﬀect was even
more pronounced in triﬂuoroethanol solutions that mimic the
membrane environment. Despite this, all mutants were equally
eﬃcient at delivering a model antigenic protein into the MHC
class I-restricted antigen presentation pathway of mouse DCs,
suggesting that the structural stability of STxB is not a key
factor in the membrane translocation process.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Like verotoxins and cholera toxin, Shiga toxin belongs to
the AB5 family of bacterial toxins [1]. Structurally, these toxins
consist of two non-covalently associated subunits, a mono-
meric catalytic A-subunit, and a pentameric B-subunit that is
responsible for receptor binding and intracellular traﬃcking
of the holotoxins [2,3]. In the case of Shiga toxin, the
A-subunit has ribosomal RNA N-glycosidase activity, leading
to protein biosynthesis inhibition, while the B-subunit (STxB)
binds speciﬁcally to the glycosphingolipid Gb3 [4]. The crystal
structures of STxB and holotoxin have been solved [5–7]. STxBAbbreviations: STxB, Shiga toxin B-subunit; CD, circular dichroism;
DC, dendritic cell; ER, endoplasmic reticulum; TFE, triﬂuoroethanol
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doi:10.1016/j.febslet.2007.11.086is a homopentamer composed of monomers of 69 residues
(7.7 kDa). Each monomer has two three-stranded antiparallel
b-sheets and an a-helix (see Fig. 1). The pentamer forms a ring-
like structure with a central pore whose diameter is about
11 A˚, and that is delimited by the ﬁve a-helices and surrounded
by b-sheets from pairs of adjacent monomers. Recent struc-
tural and mutational studies suggest that STxB has three
Gb3 binding sites per monomer [8,9].
The toxin–receptor complex is internalized via clathrin-
dependent and -independent endocytosis, and the toxin is then
transported from the early endosome to the endoplasmic retic-
ulum (ER), via the trans-Golgi network and Golgi apparatus,
a pathway known as the retrograde route [10,11]. Transport
to the ER is believed to be required for translocation of the
A-subunit to the cytosol where its molecular target – ribo-
somal RNA – resides [12]. STxB has been used as a tool for
the characterization of the retrograde route [13,14], and in bio-
medical research as a delivery tool for immunotherapy [3,15]
and cancer targeting [16,17]. It was shown that STxB delivers
exogenous peptides into the MHC class I and II pathways of
human and mouse dendritic cells (DCs) and induces humoral
and cell-mediated immune responses that protect mice from
tumor growth [18–22]. Functional TAP and proteasome activ-
ities are required for STxB-induced MHC class I-restricted
antigen presentation, strongly suggesting that STxB delivers
exogenous antigenic proteins and peptides across membranes
into the cytosolic compartment [19]. The mechanism and exact
intracellular site of this membrane translocation event have
not yet been identiﬁed, but intracellular traﬃcking studies on
human monocyte-derived DCs suggested that the retrograde
route might not be involved [23].
The interaction of STxB with membranes has been analyzed
in some detail. The two-dimensional structure of STxB on
Gb3-containing bilayer stacks overlaps perfectly with the
projection map of its solution structure [24], and the binding
of soluble Gb3 analogues does not induce structural changes
at the atomic level of resolution [8]. In agreement with these
data, no signiﬁcant conformational changes occurred upon
interaction of STxB with large unilamellar vesicles [25]. In
the latter report, a ﬂuorescence technique allowed us to mon-
itor the conformational state of STxB due to the presence of
tryptophan residues at the protein/membrane interface.
However, when triﬂuoroethanol (TFE) was used to mimic a
hydrophobic environment similar to that of membranes, ablished by Elsevier B.V. All rights reserved.
Fig. 1. Location of mutated residues in the three-dimensional structure of STxB.Structural elements shown in light grey or dark grey correspond to
diﬀerent monomers. Residues 39 and 41 are located in the a-helix, whereas residue 14 is in the b2 strand, interacting with the b6 strand of the adjacent
monomer. Residue 33 is at the protein–membrane interface.
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detected when STxB was analyzed in the absence of solvent
[27].
Here, a series of single-residue mutants at the interface
between STxB monomers was constructed. We demonstrate
that STxB pentamer stability is compromised to variable
extents in these mutants, and in some cases, this eﬀect is
particularly pronounced in membrane-mimicking conditions.
However, translocation to the cytosol does not appear to be
favored, as assessed by MHC class I-restricted antigen presen-
tation.2. Materials and methods
2.1. Cells and materials
HeLa cells were grown in Dulbeccos modiﬁed Eagles medium
containing 4.5 g/l glucose (Life Technologies Inc.) supplemented with
10% fetal calf serum (Life Technologies Inc.), 0.01% penicillin/strepto-
mycin, 4 mM glutamine, and 5 mM pyruvate in a 5% CO2 incubator.
D1 cells were cultured in Iscoves Modiﬁed Dulbeccos Medium
(Sigma), supplemented with 10% heat-inactivated fetal calf serum,
2 mM L-glutamine, 5 mM sodium pyruvate (all Invitrogen), and 30%
conditioned medium from GM-CSF-producing NIH-3T3 cells, as pre-
viously described [28].
2.2. Plasmid construction
The pSU108 plasmid was used for the construction of STxB
mutants, as described [29]. Primers encoding the desired point muta-
tions and speciﬁc primers Shiga-AtpE and Shiga-fd were used to
produce fragments that were cloned into the SphI and SalI restriction
sites of pSU108. For the construction of OVA257–264 fusion proteins,
the same strategy was used, starting with a plasmid encoding wild-type
STxB fused to OVA257–264 peptide including three amino-terminal
ﬂanking amino acids (QLESIINFEKL). Sequences derived by poly-
merase chain reaction were veriﬁed by dideoxy sequencing.
2.3. Expression, puriﬁcation, and size-exclusion chromatography of
recombinant STxB and mutants
Puriﬁcation of recombinant STxB was essentially done as described
elsewhere [30]. After preparation of periplasmic extracts, these wereloaded on a QFF column (Pharmacia) and eluted by a linear NaCl
gradient in 20 mM Tris/HCl, pH 7.5. Depending on the construction,
recombinant STxB eluted between 120 and 400 mM. STxB-containing
fractions were dialyzed against 20 mM Tris/HCl, pH 7.5, reloaded on a
Mono Q column (Pharmacia), and eluted as before. The resulting pro-
teins, estimated to be 95% pure by SDS–PAGE, were stored at 80 C
until use. Protein concentration was estimated by spectrophotometry
using an extinction coeﬃcient of 9100 M1 for STxB wild-type and
R33A, 8700 for Y14A, and 14500 for L39W and L41W. For size-
exclusion chromatography experiments, samples were loaded on a
30 ml Sephadex 75-column (GE Healthcare).
2.4. Circular dichroism spectroscopy
Far-UV (190–250 nm) circular dichroism (CD) spectra were
recorded with a Jasco J-715 spectropolarimeter coupled to a Peltier
thermal control unit. Spectra are the average of ﬁve accumulations that
all were background corrected and smoothed using the noise reduction
software of the instrument. Data were converted to molar ellipticity
per mean residue: [H] =MresHobsl
1p1, where Mres = 111.5 is the
mean residue molar mass, Hobs the measured ellipticity in millidegrees,
l the optical path length of the cell in millimetres, and p is the protein
concentration (mg/ml). Experiments were performed in a 1-mm path-
length cuvette and sample concentration of about 0.2 mg/ml. Thermal
stability curves were collected at the ﬁxed wavelength of 225 nm, and
between 40 and 90 C, with a constant heating rate of 1 C/min.
2.5. Immunoﬂuorescence
Immunoﬂuorescence was performed as previously described [11].
Brieﬂy, cells were ﬁxed at room temperature for 10 min in 3% parafor-
maldehyde, quenched with ammonium chloride, permeabilized with
0.05% saponin, incubated with the indicated primary or secondary
antibodies, mounted, and viewed by confocal microscopy (Leica
Microsystems, Mannheim, Germany).
2.6. Scatchard analysis
1 · 105 cells were placed on ice and washed once with ice-cold PBS.
The indicated concentrations of recombinant iodinated wild-type or
mutant STxB (5.000 cpm/ng; concentrations from 0.05 to 2 lM) were
added in Dulbeccos modiﬁed Eagles medium supplemented with
10% fetal calf serum. After 90 min incubation on ice in presence of
10 mMHEPES, pH 7.2, the cells were washed three times with ice-cold
PBS. Cells were lysed in 0.1 M KOH, cell-associated radioactivity and
radioactivity in the culture medium and wash solutions were counted,
and binding data were obtained as published [29].
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The presence of OVA257–264/K
b complexes at the cell surface was
determined by performing a functional assay, as described previously
[20]. Brieﬂy, D1 DCs (105 cells/well) were ﬁrst pulsed with antigen
for 5 hours and washed twice before being co-cultured with the B3Z
hybridoma (2 · 105 cells/well). A colorimetric assay with O-nitro-
phenyl b-D-galactopyranoside (ONPG, Sigma) as a substrate was used
to detect b-galactosidase activity in B3Z lysates.Fig. 2. (A) Far-CD spectra of native wild-type STxB (continuous line),
mutants (L39W: thick dotted line, Y14A: thin dashed line, L41W:
thick dashed line, R33A: thin dotted line) and thermally-denatured
STxB (thin continuous line). The inset shows the eﬀect on wild-type
STxB of increasing concentrations of TFE at 208 nm (solid symbols)
and 260 nm (open symbols) at 25 C and pH 7.0. Lines are the best ﬁt
using the two-state unfolding coupled to dissociation model (see details
in [26]). (B) Fraction of unfolded protein, monitored by changes in
ellipticity at 225 nm, as a function of temperature, for wild-type (d)
and mutants of STxB (m: L39W, n: Y14A, s: L41W, n: R33A). The
inset shows the normalized Absorbance at 280 nm as a function of the
retention volume for wild-type STxB (thick continuous line), R33A
(dotted line) and L41W mutants (thin continuous line). STxB and
mutants elute from the column at the level of the main peaks.
Table 1
Melting temperatures for the unfolding of STxB wild-type and mutants
monitored by CD spectroscopy at pH 7.0, in aqueous conditions and
in presence of 10% TFE (v/v), DTm between these two values, and






Wild-type 79.3 ± 0.3 65.6 ± 0.2 13.7 ± 0.3 136 ± 17
L39W 73.4 ± 0.2 59.2 ± 0.2 14.2 ± 0.2 201 ± 21
L41W 73.4 ± 0.3 58.3 ± 0.1 15.1 ± 0.2 87 ± 11
R33A 68.4 ± 0.1 49.3 ± 0.1 19.1 ± 0.1 838 ± 75
Y14A 68.3 ± 0.1 50.5 ± 0.2 17.8 ± 0.2 477 ± 42
CD experiments were performed at a ﬁxed wavelength of 225 nm and
0.2 mg/ml protein concentration. For Scatchard analysis, see Section 2.3. Results and discussion
3.1. Design of STxB mutants
A series of single-residue mutants of STxB were constructed
by site-directed mutagenesis. The four mutation sites are situ-
ated in interacting regions between monomers. The Y14A
mutation is located in the b-sheet monomer–monomer inter-
face, whereas R33A is located proximal to the region where
binding of Gb3 takes place. Two other mutations, L39W and
L41W, are located in the helical region. In the wild-type
protein, L39 of one monomer is localized in close proximity
of L41 of the next monomer (Fig. 1). Introducing a Trp in
these positions is expected to perturb monomer packing, if
one considers the increased size of the Trp side chain.
3.2. STxB mutants are destabilized but do not exhibit major
structural changes
Fig. 2A shows the far-UV CD spectra of wild-type STxB
and mutants at 0.2 mg/ml concentration in 20 mM phosphate
buﬀer, pH 7.0 at 25 C. Superimposition of the spectra
suggests that the secondary structure of the mutants is not per-
turbed. Furthermore, the size-exclusion chromatography pro-
ﬁles of the mutants were similar to wild-type STxB (Fig. 2B,
inset), strongly suggesting that the oligomeric state of the mu-
tants is not altered. The thermal denaturation of the mutants
was monitored by changes in ellipticity at 225 nm (Fig. 2B),
and unfolding curves were successfully ﬁtted to the two-state
unfolding model coupled to dissociation (with equations de-
tailed in [26]). Table 1 summarizes the melting temperatures
observed for each mutant protein. In all cases, a destabilization
was observed, with unfolding temperature diﬀerences ranging
from 6 to 11 C. The C-terminal fusion of STxB with the
OVA257–264 peptide does not signiﬁcantly aﬀect the CD spectra
nor the thermal denaturation curves (data not shown),
strongly suggesting that STxB structure was not altered. This
result is in good agreement with previous 2D crystallization
studies in which at 8.5A resolution, the structures of a C-termi-
nal fusion variant of STxB and of wild-type STxB were found
to be perfectly superposable [24].
We also performed thermal unfolding experiments on STxB
mutants in presence of 10% TFE (v/v) to evaluate their aﬃnity
to the more hydrophobic environment provided by the TFE/
water mixture. In a previous study, analytical ultracentrifuga-
tion experiments showed that high concentrations of TFE –
mimicking the membrane environment – induce dissociation
of wild-type STxB into monomers with high a-helical contents
[26]. However, at concentrations below 20% TFE (v/v), the
protein retains its pentameric conformation (Fig. 2A, inset).
Under our experimental conditions – 10% TFE (v/v) concen-
tration – Y14A and R33A mutants were much more destabi-
lized than wild-type STxB or L39W and L41W mutants (see
Fig. 2), suggesting these mutants have a higher propensity to
dissociate into monomers.3.3. STxB mutants retain their retrograde transport properties
and aﬃnity for Gb3
Scatchard analysis showed that the dissociation constants
of the L39W and L41W mutants are similar to that of wild-
Fig. 3. Retrograde traﬃcking analysis on wild-type STxB and the
R33A and L41W mutants. The indicated proteins (2 lM) were bound
to (A) Hela cells or (B) D1 cells on ice. The cells were washed, shifted
to 37 C for 45 min, ﬁxed, and labeled for STxB (or mutants) and the
trans-Golgi/TGN marker Rab6. Right images show overlay. STxB:
red; Rab6: green.
Fig. 4. Comparison of the respective eﬃciency of STxB and mutants
to deliver exogenous peptides into the MHC class I pathway. D1
dendritic cells (105) were pulsed for 5 h with wild-type (s) or mutant
(R33A, h; L41W, e) STxB coupled to OVA257–264, an immunodom-
inant Kb restricted OVA derived peptide. After washing, the cells were
cocultured with the speciﬁc anti-OVA257–264 B3Z hybridoma (2 · 105)
carrying a LacZ construct driven by NF-AT elements of the IL-2
promotor. A colorimetric assay with O-nitrophenyl b-D-galactopyran-
oside (ONPG, Sigma) as a substrate was used to detect b-galactosidase
activity in B3Z lysates.
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were 3- to 6-fold increased (Table 1). Despite these diﬀer-
ences, all mutants were eﬃciently internalized into both HeLa
and D1 cells, and their intracellular traﬃcking was qualita-
tively comparable to that of wild-type STxB (Fig. 3). These
results demonstrate that the mutated residues are not essential
for Gb3 binding and that retrograde transport remains eﬃ-
cient for all proteins.3.4. STxB mutants are eﬃcient at inducing MHC class I-
restricted antigen presentation
As described previously for wild-type STxB [19], we fused
the OVA257–264 peptide to the C-terminus of the R33A and
L41W mutants, and analyzed Kb-restricted antigen presenta-
tion using the B3Z hybridoma. The L41W mutant was
similarly eﬃcient as wild-type STxB at introducing the
OVA257–264 peptide into the MHC class I pathway of D1 cells,
whereas the R33A mutant was slightly less eﬃcient (Fig. 4).
This reduced eﬃciency is likely due to the apparent loss in
aﬃnity for cells of R33A (see Table 1).3.5. Conclusion
In the present study, we observed that STxB mutants whose
pentamer stability in membrane mimicking environments is
strongly reduced, are not more eﬃcient than wild-type STxB
at introducing the Kb-restricted immunodominant OVA257–
264 peptide of chicken ovalbumin into the MHC class I-
restricted antigen presentation pathway of DCs. This ﬁnding
suggests that a monomeric molten globule-like conformation
that has been observed for STxB [26] may not be the mem-
brane translocation competent intermediate of the protein.
Other mechanisms such as inverted micelle formation or endo-
somal membrane destabilization need to be considered in
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